Conversely, inhibition of GRP78 re-sensitizes B-lineage acute lymphoblastic leukemia cells that were previously refractory to vincristine8, and an inhibitor targeting GRP78’s ATPase domain has also been shown to resensitize breast cancer stem cells by inducing β-catenin proteasome degradation9. Here, HSPA5 is linked to acute lymphoblastic leukemia.